Bucillamine 可防止高危器官移植中的缺血/再灌注损伤，抑制 VEGF 的产生。 Bucillamine 是一种具有抗风湿和抗血管生成特性的口服活性巯基供体和抗氧化剂。 Bucillamine 可用于脉络膜新生血管和类风湿性关节炎的研究。

Bucillamine protects against Ischemia/reperfusion injury in high-risk organ transplants and inhibits the production of VEGF. Bucillamine is an orally active sulfhydryl donor and antioxidant with antirheumatic and antiangiogenic properties. Bucillamine can be used for studies about choroidal neovascularization and rheumatoid arthritis.

In rats subjected to liver transplants, Bucillamine significantly enhances survival and protected against hepatic injury[2]. Subconjunctival injection of Bucillamine significantly reduces the leakage and size of experimental CNV in rats[3].

65002-17-7

C7H13NO3S2

223.31

DE019;布西拉明;Thiobutarit;DE-019;DE 019;Tiobutarit;SA96

DMSO:Soluble
Powder: -20°C for 3 years
In solvent: -80°C for 2 years